|
Indications and Dosage
Oral
Pharyngitis, Tonsillitis, Uncomplicated skin and skin structure infections Adult: 200 mg bid for 10 days. Oral Community-acquired pneumonia Adult: 400 mg bid for 14 days. Oral Acute bacterial exacerbation of chronic bronchitis Adult: 400 mg bid for 10 days.
|
||||||
|
Renal Impairment
|
||||||
|
Administration
Should be taken with food.
|
||||||
|
Contraindications
Hypersensitivity to cefditoren, other cephalosporins, or milk proteins. Carnitine deficiency or an inborn error of metabolism.
|
||||||
|
Special Precautions
Patient w/ history of penicillin allergy and seizure disorder; poor nutritional status. Hepatic or renal impairment. Pregnancy and lactation.
|
||||||
|
Adverse Reactions
Diarrhoea, nausea, headache, abdominal pain, vag moniliasis, dyspepsia, vomiting, haematuria, increased urine WBC, glucose or INR, decreased haematocrit.
Potentially Fatal: Hypersensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, Clostridium difficile-associated diarrhoea and colitis. |
||||||
|
Monitoring Parameters
Monitor renal function. Observe for signs and symptoms of anaphylaxis during 1st dose.
|
||||||
|
Overdosage
Symptoms: Nausea, vomiting, epigastric distress, diarrhoea, convulsions. Management: Symptomatic and supportive treatment. Haemodialysis may be useful in the removal from the body.
|
||||||
|
Drug Interactions
Decreased absorption w/ antacids or H2-receptor antagonists. Increased plasma concentrations w/ probenecid.
|
||||||
|
Food Interaction
Increased bioavailability when given w/ a high-fat meal.
|
||||||
|
Lab Interference
May induce positive direct Comb's test. False-positive urine glucose results may occur when using Clinitest®, Benedict's or Fehling's soln. False negative result may occur in ferricyanide test.
|
||||||
|
Action
Description:
Mechanism of Action: Cefditoren binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Pharmacokinetics: Absorption: Absorbed from the GI tract. Increased bioavailability when given w/ a high-fat meal. Bioavailability: Approx 14% (fasting state). Time to peak plasma concentration: 1.5-3 hr. Distribution: Volume of distribution: 9.3±1.6 L. Plasma protein binding: 88% (primarily to albumin). Metabolism: Not appreciably metabolised. Hydrolysed by esterases to cefditoren (active component) and pivalate. Excretion: Mainly via urine by glomerular filtration and tubular secretion. Plasma half-life: Approx 1.6 hr. |
||||||
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Database. Cefditoren, CID=9571074, https://pubchem.ncbi.nlm.nih.gov/compound/Cefditoren (accessed on Jan. 21, 2020) |
||||||
|
Storage
Store at 25°C. Protect from light and moisture.
|
||||||
|
MIMS Class
|
||||||
|
References
Anon. Cefditoren. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/11/2014. Buckingham R (ed). Cefditoren Pivoxil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/11/2014. McEvoy GK, Snow EK, Miller J et al (eds). Cefditoren Pivoxil. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 05/11/2014. Spectracef Tablet, Film Coated (Vansen Pharma Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/11/2014.
|
Sign Out
